Herpes Labialis Treatment Market : TOC


Back to Report

1. Executive Summary

1.1. Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Herpes Labialis Treatment Market View Point 

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

4. North America Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027

4.1. Introduction

4.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

4.2.1. U.S.

4.2.2. Canada

4.3. Market Size (US$ Mn) Forecast By Country, 2017–2027

4.3.1. U.S.

4.3.2. Canada

4.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016

4.4.1. Acyclovir

4.4.2. Valacyclovir

4.4.3. Penciclovir

4.4.4. Famciclovir

4.4.5. Docosanol

4.4.6. Others

4.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027

4.5.1. Acyclovir

4.5.2. Valacyclovir

4.5.3. Penciclovir

4.5.4. Famciclovir

4.5.5. Docosanol

4.5.6. Others

4.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016

4.6.1. Oral

4.6.2. Topical

4.6.3. Combination

4.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027

4.7.1. Oral

4.7.2. Topical

4.7.3. Combination

4.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016

4.8.1. Hospital Pharmacies

4.8.2. Retail Pharmacies

4.8.3. Drug Stores

4.8.4. Online Pharmacies

4.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

4.9.1. Hospital Pharmacies

4.9.2. Retail Pharmacies

4.9.3. Drug Stores

4.9.4. Online Pharmacies

4.10.Market Attractiveness Analysis

4.10.1. By Country

4.10.2. By Drug Class

4.10.3. By Route of Administration

4.10.4. By Distribution Channel

4.11.Key Participants Market Presence (Intensity Map)

5. Latin America Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027

5.1. Introduction

5.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

5.2.1. Brazil

5.2.2. Mexico

5.2.3. Rest of Latin America

5.3. Market Size (US$ Mn) Forecast By Country, 2017–2027

5.3.1. Brazil

5.3.2. Mexico

5.3.3. Rest of Latin America

5.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016

5.4.1. Acyclovir

5.4.2. Valacyclovir

5.4.3. Penciclovir

5.4.4. Famciclovir

5.4.5. Docosanol

5.4.6. Others

5.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027

5.5.1. Acyclovir

5.5.2. Valacyclovir

5.5.3. Penciclovir

5.5.4. Famciclovir

5.5.5. Docosanol

5.5.6. Others

5.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016

5.6.1. Oral

5.6.2. Topical

5.6.3. Combination

5.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027

5.7.1. Oral

5.7.2. Topical

5.7.3. Combination

5.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016

5.8.1. Hospital Pharmacies

5.8.2. Retail Pharmacies

5.8.3. Drug Stores

5.8.4. Online Pharmacies

5.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

5.9.1. Hospital Pharmacies

5.9.2. Retail Pharmacies

5.9.3. Drug Stores

5.9.4. Online Pharmacies

5.10.Market Attractiveness Analysis

5.10.1. By Country

5.10.2. By Drug Class

5.10.3. By Route of Administration

5.10.4. By Distribution Channel

5.11.Key Participants Market Presence (Intensity Map)

6. Western Europe Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027

6.1. Introduction

6.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

6.2.1. Germany

6.2.2. Italy

6.2.3. France

6.2.4. Spain

6.2.5. U.K.

6.2.6. BENELUX

6.2.7. Nordic

6.2.8. Rest of Western Europe

6.3. Market Size (US$ Mn) Forecast By Country, 2017–2027

6.3.1. Germany

6.3.2. Italy

6.3.3. France

6.3.4. Spain

6.3.5. U.K.

6.3.6. BENELUX

6.3.7. Nordic

6.3.8. Rest of Western Europe

6.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016

6.4.1. Acyclovir

6.4.2. Valacyclovir

6.4.3. Penciclovir

6.4.4. Famciclovir

6.4.5. Docosanol

6.4.6. Others

6.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027

6.5.1. Acyclovir

6.5.2. Valacyclovir

6.5.3. Penciclovir

6.5.4. Famciclovir

6.5.5. Docosanol

6.5.6. Others

6.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016

6.6.1. Oral

6.6.2. Topical

6.6.3. Combination

6.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027

6.7.1. Oral

6.7.2. Topical

6.7.3. Combination

6.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016

6.8.1. Hospital Pharmacies

6.8.2. Retail Pharmacies

6.8.3. Drug Stores

6.8.4. Online Pharmacies

6.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

6.9.1. Hospital Pharmacies

6.9.2. Retail Pharmacies

6.9.3. Drug Stores

6.9.4. Online Pharmacies

6.10.Market Attractiveness Analysis

6.10.1. By Country

6.10.2. By Drug Class

6.10.3. By Route of Administration

6.10.4. By Distribution Channel

6.11.Key Participants Market Presence (Intensity Map)

7. Asia Pacific excluding Japan Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027

7.1. Introduction

7.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

7.2.1. China

7.2.2. India

7.2.3. Australia and New Zealand

7.2.4. ASEAN

7.2.5. Rest of APEJ

7.3. Market Size (US$ Mn) Forecast By Country, 2017–2027

7.3.1. China

7.3.2. India

7.3.3. Australia and New Zealand

7.3.4. ASEAN

7.3.5. Rest of APEJ

7.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016

7.4.1. Acyclovir

7.4.2. Valacyclovir

7.4.3. Penciclovir

7.4.4. Famciclovir

7.4.5. Docosanol

7.4.6. Others

7.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027

7.5.1. Acyclovir

7.5.2. Valacyclovir

7.5.3. Penciclovir

7.5.4. Famciclovir

7.5.5. Docosanol

7.5.6. Others

7.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016

7.6.1. Oral

7.6.2. Topical

7.6.3. Combination

7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027

7.7.1. Oral

7.7.2. Topical

7.7.3. Combination

7.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016

7.8.1. Hospital Pharmacies

7.8.2. Retail Pharmacies

7.8.3. Drug Stores

7.8.4. Online Pharmacies

7.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

7.9.1. Hospital Pharmacies

7.9.2. Retail Pharmacies

7.9.3. Drug Stores

7.9.4. Online Pharmacies

7.10.Market Attractiveness Analysis

7.10.1. By Country

7.10.2. By Drug Class

7.10.3. By Route of Administration

7.10.4. By Distribution Channel

7.11.Key Participants Market Presence (Intensity Map)

8. Japan Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027

8.1. Introduction

8.2. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016

8.2.1. Acyclovir

8.2.2. Valacyclovir

8.2.3. Penciclovir

8.2.4. Famciclovir

8.2.5. Docosanol

8.2.6. Others

8.3. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027

8.3.1. Acyclovir

8.3.2. Valacyclovir

8.3.3. Penciclovir

8.3.4. Famciclovir

8.3.5. Docosanol

8.3.6. Others

8.4. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016

8.4.1. Oral

8.4.2. Topical

8.4.3. Combination

8.5. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027

8.5.1. Oral

8.5.2. Topical

8.5.3. Combination

8.6. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016

8.6.1. Hospital Pharmacies

8.6.2. Retail Pharmacies

8.6.3. Drug Stores

8.6.4. Online Pharmacies

8.7. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

8.7.1. Hospital Pharmacies

8.7.2. Retail Pharmacies

8.7.3. Drug Stores

8.7.4. Online Pharmacies

8.8. Market Attractiveness Analysis

8.8.1. By Country

8.8.2. By Drug Class

8.8.3. By Route of Administration

8.8.4. By Distribution Channel

8.9. Key Participants Market Presence (Intensity Map)

9. Middle East & Africa Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027

9.1. Introduction

9.2. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

9.2.1. GCC Countries

9.2.2. South Africa

9.2.3. Rest of MEA

9.3. Market Size (US$ Mn) Forecast By Country, 2017–2027

9.3.1. GCC Countries

9.3.2. South Africa

9.3.3. Rest of MEA

9.4. Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016

9.4.1. Acyclovir

9.4.2. Valacyclovir

9.4.3. Penciclovir

9.4.4. Famciclovir

9.4.5. Docosanol

9.4.6. Others

9.5. Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027

9.5.1. Acyclovir

9.5.2. Valacyclovir

9.5.3. Penciclovir

9.5.4. Famciclovir

9.5.5. Docosanol

9.5.6. Others

9.6. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016

9.6.1. Oral

9.6.2. Topical

9.6.3. Combination

9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027

9.7.1. Oral

9.7.2. Topical

9.7.3. Combination

9.8. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016

9.8.1. Hospital Pharmacies

9.8.2. Retail Pharmacies

9.8.3. Drug Stores

9.8.4. Online Pharmacies

9.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

9.9.1. Hospital Pharmacies

9.9.2. Retail Pharmacies

9.9.3. Drug Stores

9.9.4. Online Pharmacies

9.10.Market Attractiveness Analysis

9.10.1. By Country

9.10.2. By Drug Class

9.10.3. By Route of Administration

9.10.4. By Distribution Channel

9.11.Key Participants Market Presence (Intensity Map)

10. Forecast Factors: Relevance and Impact

11. Forecast Assumptions

12. Competition Landscape

12.1.Competition Dashboard

12.2.Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)

12.2.1. Teva Pharmaceuticals, Inc.

12.2.2. Abbott Laboratories

12.2.3. Sun Pharmaceuticals Industries Ltd.

12.2.4. Mylan N.V.

12.2.5. Pfizer Inc.

12.2.6. GlaxoSmithKline plc.

12.2.7. Dr. Reddy’s Laboratories, ltd.

12.2.8. Novartis AG

12.2.9. Valeant Pharmaceuticals International Inc.

13. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Region

13.1.Introduction/Key Findings

13.2.Historical Market Size (US$ Mn) Trend Analysis By Region, 2012–2016

13.2.1. North America

13.2.2. Latin America

13.2.3. Western Europe

13.2.4. Eastern Europe

13.2.5. Asia Pacific excluding Japan

13.2.6. Japan

13.2.7. Middle East & Africa

13.3.Market Size (US$ Mn) Forecast By Region, 2017–2027

13.3.1. North America

13.3.2. Latin America

13.3.3. Western Europe

13.3.4. Eastern Europe

13.3.5. Asia Pacific excluding Japan

13.3.6. Japan

13.3.7. Middle East & Africa

13.4.Market Attractiveness Analysis By Region

14. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Drug Class

14.1.Introduction/Key Findings

14.2.Historical Market Size (US$ Mn) and Analysis By Drug Class, 2012–2016

14.2.1. Acyclovir

14.2.2. Valacyclovir

14.2.3. Penciclovir

14.2.4. Famciclovir

14.2.5. Docosanol

14.2.6. Others

14.3.Market Size (US$ Mn) and Forecast By Drug Class, 2017–2027

14.3.1. Acyclovir

14.3.2. Valacyclovir

14.3.3. Penciclovir

14.3.4. Famciclovir

14.3.5. Docosanol

14.3.6. Others

14.4.Market Attractiveness Analysis By Drug Class

15. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Route of Administration 

15.1.Introduction/Key Findings

15.2.Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2016

15.2.1. Oral

15.2.2. Topical

15.2.3. Combination

15.3.Market Size (US$ Mn) Forecast By Route of Administration, 2017-2027

15.3.1. Oral

15.3.2. Topical

15.3.3. Combination

15.4.Market Attractiveness Analysis By Route of Administration

16. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027, By Distribution Channel 

16.1.Introduction/Key Findings

16.2.Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2012–2016

16.2.1. Hospital Pharmacies

16.2.2. Retail Pharmacies

16.2.3. Drug Stores

16.2.4. Online Pharmacies

16.3.Market Size (US$ Mn) Forecast By Distribution Channel, 2017–2027

16.3.1. Hospital Pharmacies

16.3.2. Retail Pharmacies

16.3.3. Drug Stores

16.3.4. Online Pharmacies

16.4.Market Attractiveness Analysis By Distribution Channel

17. Global Herpes Labialis Treatment Market Analysis 2012–2016 and Forecast 2017–2027

17.1.Market Size and Y-o-Y Growth

17.2.Absolute $ Opportunity

17.3.Market Value Chain

Request Methodology of This Report

Request Methodology

First Time Buyer ?

Check Discount

Request a Sample

Click button below to request a sample of this report

Request Sample

About This Report


  • Rep Id : XPLREP2281
  • Publised On : March, 2018
  • No. of Pages : 218
  • Category : Healthcare
  • Publisher : Future Market Insights